Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, shares the updated results of the Phase III DESTINY-Breast03 (NCT03529110), investigating trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer. The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR) and a key secondary endpoint was overall-survival (OS). The trial had previously reported significant improvement in PFS with TDX-D compared to T-DM1, the previous second-line therapy for HER2+ metastatic breast cancer. The updated results observed a benefit in PFS of over 22 months with TDX-D compared to T-DM1. Although OS medians have not yet been reached, the OS is statistically different. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
